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Metabolic abnormalities are important to mediate the inci-
dence and development of cardiovascular diseases. In gen-
eral, glucose metabolism in the heart accounts for almost
30% of cardiac energy production and the rest of energy
(70%) to maintain cardiac function is generated from fatty
acid oxidation. In diabetes or conditions that are associated
with insulin resistance (such as obesity), glucose utilization
is compromised in the heart, while fatty acid metabolism is
upregulated, leading to abnormal lipid uptake and storage,
referred to as “lipotoxicity” which contributes to the devel-
opment of “cardiomyopathy.”
In addition, whole-body metabolic dysfunction during
diabetes or insulin resistance is associated with hyperlipi-
demia and hypertension that will also contribute to vascular
pathogenesis and coronary heart disease. Myocardial infarc-
tion or ischemia, caused by partial or complete occlusion of
coronary arteries, is a leading cause of death in the world and
often occurs in diabetic patients. Coronary artery reperfu-
sion, or reflow, is the most effective clinical intervention to
limit hypoxic injury but it simultaneously induces additional
damage to the heart, referred to as “reperfusion injury.”
Ischemia/reperfusion injury (IRI) and organ failure, espe-
cially IRI-induced remote and multiple organ failure, con-
tribute significantly to postoperativemortality andmorbidity,
and reperfusion induced oxidative stress plays a critical role
in this pathology in particular in subjects with diabetes [1, 2].
More importantly, the hearts in patients with diabetes are less
tolerant to ischemic insult and less or not responsive to pre-
or postconditioning cardioprotective interventions that are
effective in nondiabetic subjects.
Thus, the mechanisms in mediating cardiac or whole-
body metabolic alterations during diabetes or metabolic
dysfunction have important clinical implications in the
development of new therapies for diabetes relevant heart
diseases such as cardiomyopathy and myocardial ischemia-
reperfusion injury. For example, any mechanism that facili-
tates a rapid recovery of aerobic metabolism has the potential
to limit ischemia-reperfusion injury in the heart.
In this special issue, P. C. Rezende et al. evaluated
the possible influence of diabetes in myocardial ischemic
preconditioning in both experimental and clinical settings of
myocardial ischemia-reperfusion injury and proposed that
the control of metabolic changes may restore intracellular
signaling protective mechanisms in diabetes.
Atrial fibrillation (AF) is the most common abnormal
human heart arrhythmia which imposes a substantial burden
on population health, especially in patients with diabetes
[3]. However, the underlying pathophysiologicalmechanisms
of AF remain unclear. In this special issue, Y. Zhao et al.
reported their novel findings that calcineurin, together with
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its upstream molecule, calpain 2, and downstream effector,
NFAT-c3, plays a critical role in the development of AF in
patients with vascular heart disease and diabetes.
Overall, we hope that the original and review articles
presented in this special issue, representing the current
advances in metabolic mechanisms and potential therapies
of diabetic cardiovascular complication, with respect to their
potential impact in cellular survival pathways and therapeutic
strategies, will stimulate further exploration of this important
area.
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